Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has asked the US Supreme Court to review a lower court ruling in July 2013 that invalidated some of the patents for its multiple sclerosis drug Copaxone.
The patents expire in May.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Teva expects the Supreme Court to hear the case in April, a month before the Copaxone patents expire. However, the Supreme Court is unlikely to overturn the ruling by the Federal Circuit of Appeals. In November 2013, the Supreme Court rejected Teva’s motion to put a lower court ruling on hold while it decides on Teva’s appeal.
Although Copaxone’s patents expire in May, companies developing generic versions of the drug will not be able to market them before obtaining approval from the US Food and Drug Administration (FDA).
Published by Globes [online], Israel business news – www.globes-online.com